MDX 010 is not early stage phase3 trials. It is complete and awaiting results for release. And according to bmy/medx - they will file biologic license application around year end.
-- Ken B.
Ken is referring to a discussion on Wednesday's "Fast Money" involving Medarex and why shares seemed to move higher for no apparent reason. Pete Najarian speculates it's due to the promise of Medarex's new drug MDX 010. Click below to read more about the conversation and the company's Q2 Financial results.
-- Lee Brodie
Got something to say? Send us an e-mail at email@example.com and your comment might be posted on the Rapid Recap! Prefer to keep it between us? You can still send questions and comments to firstname.lastname@example.org.